Literature DB >> 7906543

Probing the active site of human IMP dehydrogenase using halogenated purine riboside 5'-monophosphates and covalent modification reagents.

L C Antonino1, K Straub, J C Wu.   

Abstract

Active-site amino acid residues of human type II inosine 5'-monophosphate dehydrogenase (IMPDH) were investigated using the covalent modification reagents 6-chloroinosine 5'-monophosphate (6-Cl-IMP) and iodoacetamide. IMPDH was incubated with these reagents in the presence and absence of IMP, NAD, and NADH, and the activity of the enzyme for IMP dehydrogenation or 2-Cl-IMP dehalogenation was followed. IMPDH activity was rapidly lost when the enzyme was incubated with the IMP analog, 6-Cl-IMP, or with iodoacetamide. The enzyme was protected against inactivation in the presence of the substrate IMP. It was not protected against inactivation by NAD alone. Saturating concentrations of IMP and NADH reduced the inactivation rate by about the same amount as with IMP alone. IMPDH samples labeled with 6-Cl-IMP and an unlabeled control were alkylated with iodoacetamide, digested with trypsin, and analyzed by HPLC-mass spectrometry (HPLC-MS). All eight cysteines of human type II IMPDH were found to exist as free sulfhydryls on the active, unlabeled form of the enzyme. At an enzyme/inactivator ratio of 1:4, only one cysteine residue, Cys-331, was found to be covalently modified by 6-Cl-IMP. From the results of the substrate protection experiments and HPLC-MS data, it is concluded that 6-Cl-IMP binds in the IMP binding site of IMPDH and reacts covalently with Cys-331 to form a purine riboside 5'-monophosphate-enzyme adduct.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7906543     DOI: 10.1021/bi00173a019

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  6 in total

Review 1.  IMP dehydrogenase: structure, mechanism, and inhibition.

Authors:  Lizbeth Hedstrom
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

2.  Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design.

Authors:  T D Colby; K Vanderveen; M D Strickler; G D Markham; B M Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

3.  Highly selective inhibition of IMPDH2 provides the basis of antineuroinflammation therapy.

Authors:  Li-Xi Liao; Xiao-Min Song; Li-Chao Wang; Hai-Ning Lv; Jin-Feng Chen; Dan Liu; Ge Fu; Ming-Bo Zhao; Yong Jiang; Ke-Wu Zeng; Peng-Fei Tu
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-03       Impact factor: 11.205

Review 4.  Mass Spectrometry-Based Protein Footprinting for Higher-Order Structure Analysis: Fundamentals and Applications.

Authors:  Xiaoran Roger Liu; Mengru Mira Zhang; Michael L Gross
Journal:  Chem Rev       Date:  2020-04-22       Impact factor: 60.622

5.  Specific biotinylation of IMP dehydrogenase.

Authors:  B Christopher Hoefler; Deviprasad R Gollapalli; Lizbeth Hedstrom
Journal:  Bioorg Med Chem Lett       Date:  2011-01-14       Impact factor: 2.823

6.  Purification and preliminary characterization of (E)-3-(2,4-dioxo-6-methyl-5-pyrimidinyl)acrylic acid synthase, an enzyme involved in biosynthesis of the antitumor agent sparsomycin.

Authors:  R J Parry; J C Hoyt
Journal:  J Bacteriol       Date:  1997-02       Impact factor: 3.490

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.